Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (181-190 of 410) with videos related to

Pageof 41
Sort By:
Nature Communications|September 13, 2023
Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targetsFilip Mihalič, Caroline Benz, Eszter Kassa, et al.
The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.
Plos Pathogens|June 20, 2014
Contribution of specific residues of the β-solenoid fold to HET-s prion function, amyloid structure and stabilityAsen Daskalov, Matthias Gantner, Marielle Aulikki Wälti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131K A Gelmon, D Stewart, K N Chi, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials GroupC M Canil, M J Moore, E Winquist, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|April 5, 2016
Eosinophilia in Pleural Effusions: a Speculative Negative Predictor for MalignancyFang-Yeh Chu, Ching-Biau Liou, Jen-Tang Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort studyMaryam Soleimani, Kevin Zou, Katherine Sunderland, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 20, 2014
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologistsTina Hsu, Peter C Black, Kim N Chi, et al.
Bioinformatics (Oxford, England)|August 18, 2016
SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNACan Kockan, Faraz Hach, Iman Sarrafi, et al.
Pageof 41

Showing results (181-190 of 410) with videos related to

Sort By:
Pageof 41
Nature Communications|September 13, 2023
Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targetsFilip Mihalič, Caroline Benz, Eszter Kassa, et al.
The Prostate|September 2, 2014
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancerArun A Azad, Raya Leibowitz-Amit, Bernhard J Eigl, et al.
Plos Pathogens|June 20, 2014
Contribution of specific residues of the β-solenoid fold to HET-s prion function, amyloid structure and stabilityAsen Daskalov, Matthias Gantner, Marielle Aulikki Wälti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131K A Gelmon, D Stewart, K N Chi, et al.
Cancer|April 23, 2008
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trialTomasz M Beer, Alshad S Lalani, Stella Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials GroupC M Canil, M J Moore, E Winquist, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|April 5, 2016
Eosinophilia in Pleural Effusions: a Speculative Negative Predictor for MalignancyFang-Yeh Chu, Ching-Biau Liou, Jen-Tang Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort studyMaryam Soleimani, Kevin Zou, Katherine Sunderland, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 20, 2014
Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologistsTina Hsu, Peter C Black, Kim N Chi, et al.
Bioinformatics (Oxford, England)|August 18, 2016
SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNACan Kockan, Faraz Hach, Iman Sarrafi, et al.
Pageof 41